49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
40 citations,
October 2020 in “Diabetes and Metabolic Syndrome: Clinical Research and Reviews” Higher androgen levels might make COVID-19 worse, especially in men.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
27 citations,
December 2020 in “Experimental Dermatology” Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
7 citations,
May 2022 in “Skin health and disease” Certain types of rashes in COVID-19 patients may indicate more severe illness and higher risk of death.
5 citations,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
5 citations,
May 2021 in “International Journal of Infectious Diseases” A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.
5 citations,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
4 citations,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
2 citations,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
2 citations,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
1 citations,
February 2023 in “JMIR. Journal of medical internet research/Journal of medical internet research” Social media data can help track COVID-19 symptoms and predict the pandemic's status.
1 citations,
January 2022 in “Turkiye Klinikleri Journal of Dermatology” Lifestyle changes during the early COVID-19 outbreak led to more cases of acne and other skin conditions, but fewer cases of rosacea and skin infections.
1 citations,
April 2021 in “International Journal of Dermatology” Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.
1 citations,
March 2021 in “The Journal of Sexual Medicine” The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.
September 2024 in “JAAD International” September 2023 in “Journal of the European Academy of Dermatology and Venereology” The Gabrin sign may help identify COVID-19 patients at high risk who also have hair loss due to male hormones.
May 2023 in “Dermatology Reports” The study found that skin conditions in COVID-19 patients can signal serious internal organ damage and may be life-threatening.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
Social media data can help track and predict COVID-19 symptoms and trends.
Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
April 2022 in “International journal of respiratory and pulmonary medicine” People with lower levels of free testosterone tend to have worse COVID-19 outcomes.
March 2022 in “medRxiv (Cold Spring Harbor Laboratory)” People with blood group O may have a higher risk of developing post-COVID-19 syndrome.
November 2021 in “Journal of the European Academy of Dermatology and Venereology” 2021 saw a slow return to normalcy and increased scientific engagement despite COVID-19 challenges.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” Third booster shots enhance the immune system's response to the COVID-19 virus.
September 2021 in “Journal of the American Academy of Dermatology” CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
August 2021 in “Journal of the American Academy of Dermatology” The study evaluated how alopecia areata severity relates to its psychosocial effects on patients.
Maidenhair fern might help with COVID-19 symptoms, but it needs more testing.